retatrutide nejm 2023 obesity trial ly3437943 Another Promising Medication (Retatrutide) for First phase 3 data for

The FDA has received reports of adverse events, some requiring hospitalization, tied to dosing errors with compounded semaglutide

This risk was notably higher in procedures involving propofol sedation, specifically upper GI endoscopies, with no significant risk noted in lower GI procedures

It performed well in GH Beauty Lab tests, increasing skin firmness by 24% in Cutometer measurements and reducing the appearance of fine lines in four weeks

One option is B12 injections

It is important to note that for older patients, tracking muscle volume may be misleading and can be a poor indicator of good progress, which is why strength , linked to metabolic function is a better metric to track